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A B S T R A C T   
Background: Worsening of anxiety and depressive symptoms have been widely described during the COVID-19 
pandemic. It can be hypothesized that vaccination could link to reduced symptoms of anxiety and/or depres-
sion. However, to date, no study has assessed this. This study aims to examine anxiety and depressive symptoms 
after vaccination in US adults, meanwhile test sociodemographic disparities in these outcomes. 
Methods: Data from the January 6-June 7 2021, cross-sectional Household Pulse Survey were analyzed. Using 
survey-weighted logistic regression, we assessed the relationships between SARS-CoV-2 vaccination and anxiety 
and/or depressive symptoms, both on overall and sociodemographic subgroups. We controlled for a variety of 
potential socioeconomic and demographic confounding factors. 
Results: Of the 453,167 participants studied, 52.2% of the participants had received the COVID-19 vaccine, and 
26.5% and 20.3% of the participants reported anxiety and depression, respectively. Compared to those not 
vaccinated, the vaccinated participants had a 13% lower odds of anxiety (adjusted odds ratio [AOR] = 0.85, 95% 
CI 0.83–0.90) and 17% lower odds of depression (AOR = 0.83, 95%CI 0.79–0.85). Disparities on the above 
associations were identified in age, marital status, education level, ethnic/race, and income level, but not on 
gender. 
Limitations: The causal inference was not able to be investigated due to the cross-sectional study design. 
Conclusion: Being vaccinated for SARS-CoV-2 was associated with lower odds of anxiety and/or depressive 
symptoms. While those more middle-aged or more affluent, were more likely to show these negative associations, 
the contrary was observed in ethnic minorities and those with lower educational attainment. More strategic and 
demography-sensitive public health communications could perhaps temper these issues.   
Introduction 
The ongoing COVID-19 pandemic urgently needs the achievement of 
global SARS-CoV-2 vaccination coverage. Given the considerable in-
crease in anxiety and depressive symptoms caused by the stress sourcing 
from the COVID-19 pandemic (Vahratian et al., 2021), it’s reasonable to 
hypothesize that the vaccination could link to reduced symptoms of 
anxiety and/or depression. However, recently reported clusters of 
anxiety-related events after administration of COVID-19 vaccine in five 
mass vaccination sites in the US reminded that the vaccination could 
conversely worse vaccinees’ mental problems (Hause et al., 2021). 
These events reported in the US violated the above hypothesis, or 
implied that there may be subgroup disparities in the association be-
tween SARS-CoV-2 vaccination and reduced symptoms of anxiety 
and/or depression. To date, no study has assessed this. In this study, we 
aim to examine anxiety and depressive symptoms after vaccination in US 
adults, meanwhile test sociodemographic disparities in these outcomes. 
Extant studies have reported on the heightened vulnerability of those 
with mental illness to coronavirus (Mazereel et al., 2021), vaccine hes-
itancy (Khubchandani et al., 2021) and vaccine efficacy amongst this 
subgroup (Mazereel et al., 2021). The present study will contribute to 
our knowledge on SARS-CoV-2 vaccination and mental health, and help 
the improvement of policy strategy of SARS-CoV-2 vaccination. 
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Methods 
Study design and participants 
This study used data from the Household Pulse Survey (HPS), a na-
tionally representative survey of adults measuring the impact of the 
COVID-19 pandemic, conducted by the U.S. Census Bureau in partner-
ship with the Centers for Disease Control and Prevention. The HPS used 
the US Census Bureau’s Master Address File as the source of sampled 
housing units. The sample design was a systematic sample of all eligible 
housing units, with adjustments applied to the sampling intervals to 
select a large enough sample to create representative estimates at the 
national, state, and metropolitan area levels. Technical details are 
available on the Census Bureau website (Hause et al., 2021). HPS was 
administered online and gathered demographic, social, economic and 
health information, week of the interview, and state of origin. We uti-
lized HPS data spanning January 6 through June 7 2021, which also 
includes COVID-19 vaccine-related queries. 
The data are publicly available. The use of secondary de-identified 
data making this study exempt from institutional review board review. 
This study follows the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) reporting guideline (STROBE 
checklist for cohort studies, 2007). 
Measures 
Vaccination status was qualitatively assessed by the question “Have 
you received a COVID-19 vaccine?” with the response yes or no. Ques-
tions on mental health symptoms were based on the validated two-item 
Generalized Anxiety Disorder for anxiety and two-item Patient Health 
Questionnaire for depression. Both scores range from 0 to 6, and a score 
≥3 on each scale indicates a high probability of the disorder (Kroenke 
et al., 2003; Kroenke et al., 2007). 
Statistical analyze 
We report categorical variables as number (percentage), and 
continuous variables mean (standard deviation). Survey weighting per 
wave was used to account for sampling design (including the unequal 
probability of selection, clustering, and stratification). 
To estimate the association between vaccination and mental health 
outcomes, we fitted weighted logistic models with anxiety or depression 
as the dependent variables, and vaccination status as the predictor, 
controlling for covariates, including age, gender, race/ethnicity, 
educational attainment, marital status, household income, history of 
COVID-19 infection, week of the interview, and state of origin. To es-
timate subgroup disparities in the above association, we fitted similar 
models but adding an interaction between interested subgroup factors 
and vaccination status. 
We also repeated the above analyses for each state. 
All analyses were performed using R, version 3.6.0. We report two- 
sided P values and 95% confidence intervals (CIs) throughout. P <
0.05 was considered to be statistically significant. 
Results 
Of the 453,167 participants studied, most identified as women 
(59.7%), White (78.3%), and were aged between 45 and 65 (41.7%). 
52.2% of the participants had received the COVID-19 vaccine. 26.5% of 
the participants reported anxiety and 20.3% reported depression 
(Table 1). 
Compared to those not vaccinated, the vaccinated cohort had a 15% 
lower odds of anxiety (adjusted odds ratio [AOR] = 0.85, 95%CI 
0.83–0.90) and 17% lower odds of depression (AOR = 0.83, 95%CI 
0.79–0.85). These negative associations were stronger in participants 
aged ≥45, widowed/divorced/separated, and of higher income bracket 
(AORs < 1, p < 0.05) (Table 2). 
Compared to White respondents, vaccination among Black re-
spondents was associated with an additional 23% higher odds of anxiety 
(AOR = 1.23, 95CI% 1.12–1.35), and among Hispanic respondents was 
associated with an additional 15% higher odds of anxiety (AOR = 1.15, 
95CI% 1.05–1.26) and 27% higher odds of depression (AOR = 1.27, 
95CI% 1.15–1.39). These positive associations were stronger in people 
with lower educational background (AORs > 1, p < 0.05) (Table 2). 
No gender disparities were found (Table 2). 
The state-specific analysis indicated that the above association and 
subgroup disparities have obvious geographic variance (Supplement). 
Discussion 
Here we demonstrated that being vaccinated for SARS-CoV-2 was 
associated with lower odds of anxiety and/or depressive symptoms, and 
this association varied among states. While those more middle-aged or 
more affluent, were more likely to show these negative associations, the 
contrary was observed in ethnic minorities and those with lower 
educational attainment. 
Our hypotheses regarding the association between SARS-CoV-2 
vaccination and reduced symptoms of anxiety and/or depression were 
confirmed by our analysis (Table 2). Although we don’t have corre-
sponding variables to enable us to verify the possible mechanism, it’s 
easy to understand that the SARS-CoV-2 vaccination reduced people’s 
fear of COVID-19 or related constrain resulting from COVID-19 con-
trolling, and then reduced vaccinees’ mental problems. The supplement 
result indicated an obvious variation of the above association among 
states. This variation to some extent keeps in line with the variation of 
confirmed COVID-19 cases and different anti-COVID-19 measures took 
Table 1 
Characteristics of Participants. Data are from the household pulse survey among 
adults 18 or older spanning January 6 through June 7 2021.  
Characteristic No. (%) of participants 
Gender(¼ Female) 270 350(59.7) 
Age  
18–44 134 518(29.7) 
45–65 189 125(41.7) 
65+ 129 524(28.6) 
Race/ethnicity  
White 354 914(78.3) 
Black 31 443(6.9) 
Asian 17 996(4) 
Hispanic 34 402(7.6) 
Other 14 412(3.2) 
Education attained  
Less than high school 2 233(0.5) 
Some high school 4 937(1.1) 
High school graduate or equivalent 47 886(10.6) 
Some college, but degree not received or is in progress 92 299(20.4) 
Associate’s degree 48 081(10.6) 
Bachelor’s degree 135 068(29.8) 
Graduate degree 122 663(27.1) 
Marital Status  
Married 270 527(59.7) 
Never married 78 235(17.3) 
Widowed/divorced/separated 104 405(23) 
Total household income before taxes  
Less than $25,000 45 179(10) 
$25,000 - $34,999 39 007(8.6) 
$35,000 - $49,999 49 706(11) 
$50,000 - $74,999 81 244(17.9) 
$75,000 - $99,999 66 700(14.7) 
$100,000 - $149,999 83 431(18.4) 
$150,000 - $199,999 40 563(9) 
$200,000 and above 47 337(10.4) 
History of doctor-confirmed COVID-19 infection 48 076(10.6) 
Vaccine received 236 757(52.2) 
Anxiety present 119 883(26.5) 
Depression present 91 964(20.3)  
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by states (Hallas et al., 2020), and also keeps in line with the 
anxiety-related events which only reported in part of vaccination sites in 
the US (Hause et al., 2021). 
Older people and people widowed/divorced/separated have a 
stronger association between SARS-CoV-2 vaccination and reduced 
symptoms of anxiety and/or depression (Table 2). These results are 
consistent with previous studies, which concluded that these groups are 
more vulnerable to COVID-19 and are more likely to express willingness 
to be vaccinated against COVID-19 (Geriatric Medicine Research et al., 
2021; Fisher et al., 2020; Wu et al., 2021; Holingue et al., 2020). 
No gender disparity was found on the association between SARS- 
CoV-2 vaccination and reduced symptoms of anxiety and/or depres-
sion (Table 2), although females were found to suffer greater psycho-
logical distress during the COVID-19 pandemic (Holingue et al., 2020). 
This result also to some extent consistent with previous studies which 
concluded that females face additional stress sources than males (Wade 
et al., 2021; Hong et al., 2021), likes the difficulty to separate their work 
and family lives due to the pressure of traditional gender roles during the 
COVID-19 pandemic, and part of these additional stress source cannot be 
alleviated by reducing the fear on SARS-CoV-2. 
Interestingly, although low-income people suffered more psycho-
logical distress from the COVID-19 (Holingue et al., 2020; McGinty 
et al., 2020), higher-income people benefit more from the association 
between SARS-CoV-2 vaccination and reduced symptoms of anxiety 
and/or depression (Table 2). In addition, vaccination among ethnic 
minorities and those with lower educational attainment associated with 
additional higher odds of anxiety or depression (Table 2). We suspect all 
of these could be an incidental effect arising from vaccine hesitancy that 
is more prevalent in these group people (Khubchandani et al., 2021; 
Fisher et al., 2020), and equally, unclarity and/or misinformation sur-
rounding vaccination side effects (Hause et al., 2021; Hotez et al., 2021). 
Anxiety-related events can occur after any vaccination (Hause et al., 
2021). It is important for vaccination providers to aware that 
anxiety-related adverse events might occur if vaccinees unclear the 
possible adverse reactions, especially now that misinformation about 
the safety and effectiveness of vaccines is circulating everywhere (Hotez 
et al., 2021). Besides the recommended minimum of 15 min for obser-
vation of any adverse reactions after vaccination (Shimabukuro and 
Nair, 2021), more strategic and demography-sensitive public health 
communications for post-15 min are also needed. 
The state-specific analysis presents further detailed information on 
which group of people should be focused on (Supplement). For instance, 
Table 2 
Association between SARS-CoV-2 vaccination and anxiety or depressive disor-
ders, as well as sociodemographic disparities, January 6- June 7 2021,. Data are 
from the household pulse survey among adults 18 or older spanning January 6 
through June 7 2021,. Covariates controlled for included age, gender, race/ 
ethnicity, educational attainment, marital status, household income, history of 
COVID-19 infection, week of interview, and state of origin. (AOR, adjusted odds 
ratio; CI, confidence interval.).  
Characteristic Anxiety(¼ TRUE) Depression(¼ TRUE) 
AOR (95% 
CI) 
p AOR (95% 
CI) 
p 
Main effect     
Vaccine received (=No) Reference Reference Reference Reference 





Subgroup disparity     
Age     
Vaccine (=Yes) × age 
(=18–44) 
Reference Reference Reference Reference 




< 0.0001 0.90(0.85, 
0.97) 
0.0024 




< 0.0001 0.74(0.68, 
0.80) 
<0.0001 
Gender     
Vaccine (=Yes) × gender 
(=Male) 
Reference Reference Reference Reference 







Marital Status     
Vaccine (=Yes) × marital 
status(=Married) 
Reference Reference Reference Reference 















Race/ethnicity     
Vaccine (=Yes) × race/ 
ethnicity (=White) 
Reference Reference Reference Reference 























































college, but degree Yet 


























Reference Reference Reference Reference 
Total household income 




Reference Reference Reference Reference 
0.1119 0.1253  
Table 2 (continued ) 
Characteristic Anxiety(¼ TRUE) Depression(¼ TRUE) 
AOR (95% 
CI) 




















































(=$200,000 and above) 
0.76(0.67, 
0.84) 
< 0.0001 0.73(0.64, 
0.83) 
< 0.0001  
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although there is no statistical difference at the national level, females in 
California and Michigan associated with additional higher odds of 
anxiety or depression after SARS-CoV-2 vaccination. The educational 
subgroup disparity mainly occurred in Lowa, Massachusetts, Minnesota, 
New Hampshire, Ohio, Pennsylvania, Texas, Vermont, and Wisconsin. 
The race/ethnicity subgroup disparity mainly occurred in Alabama, 
Connecticut, Georgia, Lowa, Louisiana, Nevada, New Jersey, North 
Carolina, Oklahoma, South Dakota, Texas, Vermont, Virginia, Wiscon-
sin, and Wyoming. Although at the national level affluent people benefit 
more from the association between SARS-CoV-2 vaccination and 
reduced symptoms of anxiety and/or depression, the situation reversed 
in states including Louisiana and Rhode Island. 
Strength and limitations 
To our knowledge, this is the first study to systemically assess the 
mental health outcomes after SARS-CoV-2 vaccination using national 
representative data. This study contributes to our understanding of the 
role of SARS-CoV-2 vaccination as a protective factor for the reduction 
of anxiety and/or depression. The subgroup analysis allowed more 
nuanced and practical public health policy strategies. 
A key study limitation is the cross-sectional design and lack of pre- 
vaccination measures for the vaccinated cohort, precluding any causal 
inference i.e. is vaccination leading to the lower likelihood of anxiety or, 
were those less anxious and/or depressed more likely to get vaccinated 
in the first place. Other limitations include possible confounders unac-
counted for (e.g. psychiatric and non-psychiatric comorbidities), and the 
lack of clinical confirmation as data was drawn from large-scale popu-
lation survey using self-administered instruments. Finally, dataset lim-
itation also hindered sensitivity testing of findings against lifestyle 
variables e.g. life stressors that could potentially explain correlations 
observed. 
Conclusion 
Being vaccinated for SARS-CoV-2 was associated with lower odds of 
anxiety and/or depressive symptoms, but existed subgroup disparities to 
the disadvantage of ethnic minorities and those with lower educational 
attainment. More strategic and demography-sensitive public health 
communications could perhaps temper these issues. 
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